Biomedical literature, made navigable
Discover articles through diseases, drugs, treatments, interventions, clinical instruments, institutions and funders extracted from the BMJ open corpus.
An entity family is a category of extracted information. Choose one to browse its named entities and supporting articles.
Organisations named as supporting, sponsoring, or funding research.
5,089 articles · 9,137 mentionsInstitutionsUniversities, hospitals, research centres, networks, and public bodies.
11,350 articles · 22,378 mentionsDrugsNamed medicines, compounds, vaccines, and pharmacological agents.
10,506 articles · 58,393 mentionsDiseasesNamed diseases, disorders, syndromes, injuries, and health conditions.
23,712 articles · 125,551 mentionsTreatmentsClinical therapies and care approaches used to manage a condition.
7,227 articles · 16,644 mentionsInterventionsProgrammes, procedures, policies, and other actions being evaluated.
4,132 articles · 9,994 mentionsClinical instrumentsNamed questionnaires, scales, scores, indices, and other clinical outcome assessments.
945 articles · 1,957 mentionsChoose an entity to see the articles in which it was identified.
…n. It is noticed that two patients switched from ocrelizumab to ofatumumab: one due to infusion-related adverse effects and another for lo…
…als, leading to an ongoing need to develop novel antibiotics. 1 Gepotidacin is a first-in-class oral antibiotic that was approved recently …
…assurance regarding the safety of GLP-1 RA use in patients with type 2 diabetes.…
…s clinic for new-onset T1D without DKA 2–5 days after beginning insulin (n=14). Children with chronic T1D and glycated hemoglobin <8.0%…
…for metabolite monitoring and vigilance when prescribing AZA in SLE pregnancies.…
… points; 95% confidence interval [CI], 12.5 to 33.6; P<0.0001). Obinutuzumab was superior to placebo with statistically significant benefit …
…ths after rituximabConclusions In patients with thrombotic APS, rituximab treatment may prevent thrombotic recurrence with a significant …
…otic and/or immunosuppressive therapy; post-VHD treatments were aspirin (48.6%), anticoagulants (50%), hydroxychloroquine (86.1%), gluc…
…Objectives Type I-III interferons (IFNs) are key mediators in systemic lupus erythematosus (SLE) and have been proposed to contribute to cardiovascular di…
…d HCQ 400 mg/day. In August 2025, due to inadequate efficacy of rituximab (3 g), intolerance to MMF, and limitations on IS (due to leukop…
…iated thrombocytopenia.Methods A 57-year-old Chinese woman with Rhupus (diagnosed 2010, with high RF, anti-CCP, and anti-dsDNA) presen…